Ingevity Corp director Francis David Segal received 335 vested deferred stock units (DSUs) on October 1, 2026, in lieu of quarterly director fees, following his election to receive DSUs instead of those fees. The transaction lists $71.09 per share, and Segal’s reported direct position following the transaction was 8,947 shares.
Ingevity Corp director J. Kevin Willis received 405 vested deferred stock units on October 1, 2026, reported at $71.09 per share. The units were granted in lieu of quarterly director fees and will settle into an equal number of common shares upon termination of board service. His reported post-transaction position was 11,883 shares.
Ingevity Corp (NGVT) reported that President & CEO David H. Li sold company common stock in three open-market transactions under a Rule 10b5-1 trading plan. On August 14, 2026 he sold 5,000 shares at a weighted average price of $75.73, with individual trades between $74.82 and $76.53. On August 17, 2026 he sold another 5,000 shares at a weighted average price of $75.83, with prices between $75.50 and $76.25. On August 18, 2026 he sold 92 shares at a weighted average price of $74.71, with trades between $74.39 and $74.96. In total, the filing reports sales of 10,092 shares of NGVT common stock held directly by Li.
Ingevity Corp President & CEO David H. Li reported open-market sales of company common stock under a Rule 10b5-1 trading plan. He sold 5,000 shares on August 12, 2026 at a weighted average price of $76.62 and 5,000 shares on August 13, 2026 at a weighted average price of $75.73, each executed through multiple trades within disclosed price ranges.
Ingevity Corp officer Phillip John Platt, SVP and Chief Financial Officer, reported a Form 4 transaction involving company common stock. On 2026-08-10, 1,698 shares were withheld by the company at $77.04 per share to satisfy tax withholding obligations related to 2024 restricted stock units that vested. Following this tax-withholding disposition, Platt’s directly held common stock position is 26,641 shares.
Ingevity Corp executive Ryan C. Fisher, SVP, General Counsel & Secretary, reported selling a total of 2,709 shares of common stock on August 3, 2026. The sales occurred in two non-derivative transactions classified as sales in open market or private transactions at $73.7600 and $73.6700 per share. The Rule 10b5-1 trading plan checkbox was not checked for these trades.
Ingevity Corporation reported second‑quarter 2026 net sales of $314.1 million and net income from continuing operations of $39.8 million, compared with a loss a year earlier that had included a large goodwill impairment. Including discontinued operations, net income was $35.3 million for the quarter and $95.1 million year‑to‑date.
Results reflect portfolio changes and significant special items. The company completed the all‑cash sale of its industrial specialties product line, classified as discontinued operations, recognizing a $54.2 million gain, and sold its road markings product line for $63.2 million, recording an $8.6 million gain in continuing operations. In the Advanced Polymer Technologies segment, a sale process triggered a fair‑value review and a $32.1 million non‑cash long‑lived asset impairment. Segment EBITDA for the quarter totaled $122.7 million, led by Performance Materials at $86.1 million.
Operating activities used $15.8 million of cash in the first half, largely due to a $113.2 million litigation settlement payment to BASF related to prior antitrust counterclaims. Investing activities provided $181.7 million, mainly from divestiture and restricted investment proceeds. Total debt including finance leases was $1,202.8 million, with net leverage of 2.5 and interest coverage of 6.8 under credit‑agreement definitions. The company repurchased 1,265,189 shares for $87.4 million under its $500.0 million authorization.
Ingevity Corporation reported strong second quarter 2026 results. Net sales from continuing operations were $314.1 million, down 5% mainly due to the Road Markings divestiture; excluding that product line, sales increased 5%. Net income from continuing operations was $39.8 million, or $1.13 diluted EPS, compared with a loss of $(141.4) million, or $(3.87) per diluted share, a year earlier. Adjusted EBITDA from continuing operations rose to $115.0 million, with margin expanding to 36.6% from 30.5%.
Performance Materials sales increased 4% to $160.6 million, with segment EBITDA of $86.1 million and a 53.6% margin. Pavement Technologies sales declined to $104.2 million due to the Road Markings sale, but excluding that divestiture grew 3%, with EBITDA of $25.4 million and a 24.4% margin. Advanced Polymer Technologies sales grew 14% to $49.3 million, and segment EBITDA improved to $11.2 million, lifting margin to 22.7%.
Operating cash flow was a negative $15.8 million, driven by a $113.2 million litigation settlement payment; excluding this, free cash flow was $89.1 million. The company repurchased about $35 million of shares and ended the quarter with a Net Debt Ratio of 2.5x. Ingevity raised its 2026 outlook to net sales of $1.05–$1.15 billion, adjusted EBITDA of $380–$400 million, diluted adjusted EPS of $5.00–$5.45, and free cash flow of $220–$245 million (excluding the litigation settlement).